Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
Lancet. 2020.
PMID: 33278935
Clinical Trial.
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
Cescon DW, Schmid P, Rugo HS, Im SA, Md Yusof M, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Haiderali A, Zhou X, Guo Z, Nguyen AM, Cortes J.
Cescon DW, et al. Among authors: otero mt.
J Natl Cancer Inst. 2024 May 8;116(5):717-727. doi: 10.1093/jnci/djad240.
J Natl Cancer Inst. 2024.
PMID: 38070159
Clinical Trial.
Item in Clipboard
Kidney Transplantation and Obesity: Are There Any Differences in Outcomes?
Moein M, Otero MT, Rood GJ, Hanlon M, Saidi R.
Moein M, et al. Among authors: otero mt.
World J Surg. 2023 Feb;47(2):510-518. doi: 10.1007/s00268-022-06806-4. Epub 2022 Oct 20.
World J Surg. 2023.
PMID: 36264336
Item in Clipboard
Cite
Cite